TUDCA Benefits: What the Trials Measured and What They Never Did

TUDCA benefits in human trials are real but narrow. It raised liver and muscle insulin sensitivity about 30% in obese adults, and people handled it well. Yet no trial has measured a liver or gut result. Its fame is borrowed from ursodiol, a different prescription drug. And the liver cleanses sold next to it make soap, not stones.

Search for TUDCA benefits or a liver cleanse and you land on the same shelf, sold on the same promise. Your liver is clogged, and this unclogs it. One product on that shelf even hands you proof you can hold in your hand.

A woman in her forties had gallstones confirmed on ultrasound. Then she tried an olive oil and citrus flush. She sent the green stones she passed to a lab. They had no crystal structure. They were mostly fatty acids, with no cholesterol, bilirubin or calcium. Researchers then made the same objects on a lab bench from oleic acid, lemon juice and potassium hydroxide. She had made soap, and she still had her gallstones.

I’m Dr. Gurpreet Singh Padda, MD, MBA, MHP. The Chapter 28 video of The Angry Gut, The Liver Flush Is Soap, works through the whole shelf. Here the question is what the human trials behind these bottles measured. And which numbers in your own blood work should decide whether anything works?

A liver cleanse that manufactures its own proof

That is a single case report. But the chemistry does not care how many testimonials disagree.

The cleanse treats bile as sludge to flush out. But bile is a defense and a signal. It breaks up fat and carries fat-soluble vitamins in. It helps keep bacterial debris out of the blood. It shapes which microbes can live in the bowel. The biology of that signal is covered in why bile acts as a hormone the liver listens to. The real question is whether anything in a bottle restores it.

TUDCA is not ursodiol, whatever the label implies

Ursodeoxycholic acid, sold as ursodiol, is a prescription drug with a real use. Tauroursodeoxycholic acid, TUDCA, is its close cousin bound to taurine. It is sold as a supplement, mostly on the drug’s fame. So start with what the drug itself does in its home disease, primary biliary cholangitis (a slow attack on the liver’s bile ducts).

Pooled across trials, deaths ran 45 of 699 on the drug and 46 of 692 without it. That is a relative risk of 0.97. Death or transplant combined did not change. Neither did itch or fatigue. Alkaline phosphatase, a liver enzyme, dropped by 257 U/L. One tissue result did move. Worsening of liver stage happened in 66 of 281 treated patients against 103 of 270 controls, a relative risk of 0.62. But only one of those trials had low risk of bias.

None of those patients took TUDCA. An industry borrowed the trials and charges for the likeness, and nothing on the bottle has to say so.

What are the benefits of TUDCA in human trials?

The metabolic trial took 20 obese adults with a mean body mass index of 37. At 1,750 mg a day for four weeks, insulin sensitivity in liver and muscle rose by about 30%. Fat tissue did not respond. The cell stress markers the study was built around did not budge. So the effect was real, and the proposed reason was not.

The nerve trial gave 2 g a day for sixteen weeks to people with progressive multiple sclerosis. It studied 47 of them, 26 on the supplement and 21 on placebo. Side effects did not differ. It was absorbed, and immune cells and gut bacteria shifted. Clinical and spinal fluid results showed no real difference.

That is early human evidence, and it is worth acting on. TUDCA gets in, people tolerate it, and it moves metabolic and immune measures. Neither trial measured a single liver or gut result. If you take it for your liver, you are guessing from muscle and white blood cells.

Name the number before you start the bottle

The most useful trial in this whole file was not about a supplement. Researchers took 100 people with primary biliary cholangitis who were already on ursodiol. They were still failing an agreed response standard. Then they added either bezafibrate or placebo for two years, while everyone stayed on the original drug.

Complete response on blood tests reached 31% with bezafibrate and 0% with placebo. Alkaline phosphatase went back to normal in 67% against 2%. The add-on had a cost: muscle pain ran 20% against 10%.

The placebo group stayed on standard treatment for two years, and almost nothing went back to normal. The lack of response was visible in blood work the whole time. The lesson for any bile agent, prescription or bottle, is simple. Write down which number should move and by when. Then check it. Any change to a prescription goes through your physician.

Does milk thistle work once the weak trials come out?

A Cochrane review pooled 18 randomized trials and 1,088 patients with alcohol-related or viral liver disease. Liver-related deaths looked like a win across all trials, a relative risk of 0.50 with a range of 0.29 to 0.88. Limited to high-quality trials, it became 0.57 with a range of 0.28 to 1.19. The size held. The certainty did not.

A trial funded by the National Institutes of Health, in 154 people with hepatitis C, found response rates of 4.0% and 3.8% on two high doses. Placebo got 3.8%. A 2025 review of 55 studies and 3,545 patients found drops in liver enzymes in fatty liver and viral hepatitis. It found none in drug-caused or alcohol-related injury, no effect on alkaline phosphatase, and none at a body mass index of 30 or above. Doses under 400 mg did better than larger ones. That backward pattern usually points to small-study noise, not biology.

The terrain question nobody has measured

Bile and gut microbes move together. One study compared 47 people with cirrhosis to 14 controls. Advanced disease had the lowest secondary bile acids, which are the products bacteria make from bile. Ruminococcaceae tracked the deoxycholic to cholic acid ratio at r=0.82. The organisms doing the chemistry rise and fall with what they make. It is a snapshot study, and stool bile acids are a downstream readout. So the head count is not the activity.

Under every bottle sits a claim nobody has tested. No herbal, dietary or drug agent has been shown to raise measured bile flow in a living person. That trial has not been run for money reasons as much as science reasons. The person who needs the answer comes with metabolic disease, a medicine list and a shelf of supplements. Clean groups are cheaper to recruit and easier to publish. One trial would change my view. It would take people with measured bile acid malabsorption, test a bile agent against placebo, and measure bile output directly.

Before the next bottle

• Write down the marker that should move, such as alkaline phosphatase, bilirubin or liver enzymes, and a date to recheck it.
• Ask whether a supplement was tested in your condition.
• Put the metabolic terrain first. You cannot out-inject a broken metabolism, and a pill does not out-supplement one.

A fatty liver and a stalled bile supply share one terrain with insulin resistance. That is why the same treatment can work in one body and fail in another. The previous post, on why the weeds were never the problem, sets up this one. How to heal a leaky gut once drainage works comes next. Every trial named here, with full numbers and the limits of each, is in the Chapter 28 Deep Dive.

Frequently asked questions

Is TUDCA the same as ursodiol?

No. Ursodiol is ursodeoxycholic acid, a prescription drug. TUDCA is the form bound to taurine, sold as a supplement. Most results people quote belong to ursodiol in primary biliary cholangitis. There it moved blood tests but not deaths, itch or fatigue. TUDCA’s own human trials are small. They measured insulin action and immune cells, not the liver. The metabolic audit shows which markers are worth tracking instead.

Does milk thistle lower liver enzymes?

A little, in some people. A review of 55 studies found drops in AST and ALT in fatty liver and viral hepatitis. But it found no change in alkaline phosphatase and no effect at a body mass index of 30 or above. Its apparent benefit on deaths lost certainty when only high-quality trials were counted. Safety was about the same as placebo every time. Why a normal GGT result is not the same as a healthy liver adds context.

Do liver cleanses really flush out gallstones?

The best-studied case says no. The green objects passed after an olive oil and citrus cleanse were mostly fatty acids. They had none of the cholesterol, bilirubin or calcium in real gallstones. And they could be made again on a lab bench. The woman who passed them still had her stones. Gallstone disease also travels with fatty liver and metabolic syndrome. Metabolic inflammation is the terrain behind both.

Does bile change the gut microbiome?

Yes, in the direction you would expect. In cirrhosis, bile delivery falls. Secondary bile acids dropped, and the bacteria families that change bile acids declined. Enterobacteriaceae rose. Certain organisms tracked certain bile acids. That study was a snapshot, so it cannot say which changed first. And a stool readout is not what the small bowel went through. What a stool microbiome report can and cannot tell you explains that limit.

Is cascara sagrada safe to use long term?

Nobody knows, and that is the problem. Cascara lost its over-the-counter laxative status in 2002. The requested data on genetic damage and cancer were never turned in. That is a gap in evidence, not a finding of harm. But it leaves a daily-use product with no safety file. Any laxative plan belongs in a talk with your physician. How some pain medications stall the gut covers a common reason people reach for one.

Is it safe to take TUDCA daily?

In the two human trials behind it, people handled daily TUDCA well. One used 1,750 mg a day for four weeks in obese adults. The other used 2 g a day for sixteen weeks in progressive multiple sclerosis, and side effects did not differ from placebo. Neither trial ran longer or measured the liver. So those results say nothing about years of daily use. Review any daily supplement with your physician.

Which is better, TUDCA or milk thistle?

Neither has earned that title for the liver. TUDCA’s human trials measured insulin sensitivity and immune cells, not a liver result. Milk thistle lowered liver enzymes in fatty liver and viral hepatitis. But its benefit on deaths lost certainty in high-quality trials. And it did nothing at a body mass index of 30 or above. Pick the marker that should move, then recheck it on a set date.

How long does it take for TUDCA to work?

In the metabolic trial, liver and muscle insulin sensitivity rose about 30% after four weeks at 1,750 mg a day. That is the only measured timeline, and it was not a liver result. If you take it, name the marker you expect to move, such as liver enzymes or alkaline phosphatase. Set a recheck date before the first capsule. The metabolic audit lists the markers worth tracking.

Sources

1. Sies, C. W., & Brooker, J. (2005). Could these be gallstones?. Lancet, 365(9468), 1388. https://doi.org/10.1016/S0140-6736(05)66373-8
2. Rudic, J. S., Poropat, G., Krstic, M. N., Bjelakovic, G., & Gluud, C. (2012). Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database of Systematic Reviews, 12(12), CD000551. https://doi.org/10.1002/14651858.CD000551.pub3
3. Kars, M., Yang, L., Gregor, M. F., Mohammed, B. S., Pietka, T. A., Finck, B. N., Patterson, B. W., Horton, J. D., Mittendorfer, B., Hotamisligil, G. S., & Klein, S. (2010). Tauroursodeoxycholic acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes, 59(8), 1899-1905. https://doi.org/10.2337/db10-0308
4. Ladakis, D. C., Harrison, K. L., Smith, M. D., Solem, K., Gadani, S., Jank, L., Hwang, S., Farhadi, F., Dewey, B. E., Fitzgerald, K. C., Sotirchos, E. S., Saidha, S., Calabresi, P. A., & Bhargava, P. (2025). Bile acid metabolites predict multiple sclerosis progression and supplementation is safe in progressive disease. Med, 6(3), 100522. https://doi.org/10.1016/j.medj.2024.09.011
5. Corpechot, C., Chazouillères, O., Rousseau, A., Le Gruyer, A., Habersetzer, F., Mathurin, P., Goria, O., Potier, P., Minello, A., Silvain, C., Abergel, A., Debette-Gratien, M., Larrey, D., Roux, O., Bronowicki, J. P., Boursier, J., de Ledinghen, V., Heurgue-Berlot, A., Nguyen-Khac, E., … Poupon, R. (2018). A placebo-controlled trial of bezafibrate in primary biliary cholangitis. New England Journal of Medicine, 378(23), 2171-2181. https://doi.org/10.1056/NEJMoa1714519
6. Rambaldi, A., Jacobs, B. P., & Gluud, C. (2007). Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. Cochrane Database of Systematic Reviews, 2007(4), CD003620. https://doi.org/10.1002/14651858.CD003620.pub3
7. Fried, M. W., Navarro, V. J., Afdhal, N., Belle, S. H., Wahed, A. S., Hawke, R. L., Doo, E., Meyers, C. M., & Reddy, K. R. (2012). Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial. JAMA, 308(3), 274-282. https://doi.org/10.1001/jama.2012.8265
8. Shahsavari, K., Ardekani, S. S., Ardekani, M. R. S., Esfahani, M. M., Kazemizadeh, H., Jamialahmadi, T., Iranshahi, M., Khanavi, M., & Hasanpour, M. (2025). Are alterations needed in Silybum marianum (Silymarin) administration practices? A novel outlook and meta-analysis on randomized trials targeting liver injury. BMC Complementary Medicine and Therapies, 25(1), 134. https://doi.org/10.1186/s12906-025-04886-y
9. Kakiyama, G., Pandak, W. M., Gillevet, P. M., Hylemon, P. B., Heuman, D. M., Daita, K., Takei, H., Muto, A., Nittono, H., Ridlon, J. M., White, M. B., Noble, N. A., Monteith, P., Fuchs, M., Thacker, L. R., Sikaroodi, M., & Bajaj, J. S. (2013). Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. Journal of Hepatology, 58(5), 949-955. https://doi.org/10.1016/j.jhep.2013.01.003
10. U.S. Food and Drug Administration, Department of Health and Human Services (2002). Status of certain additional over-the-counter drug category II and III active ingredients. Final rule. Federal Register, 67(90), 31125-31127 (FR Doc No: 02-11510). https://www.govinfo.gov/content/pkg/FR-2002-05-09/html/02-11510.htm

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, board certified in anesthesiology, pain medicine, interventional pain management, addiction medicine and obesity medicine. Adapted from Chapter 28 of The Angry Gut by Dr. Padda and Ami Michelle Grimes. Last reviewed September 2026.